Press Release FeedGet the RSS feed
Menu

Business Wire

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Business Wire

Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer

FREMONT, Calif., October 21, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3 study in cutaneous squamous cell carcinoma, as well as a Rapid Oral presentation from B-STRONGER-1, a prospective, multicenter study evaluating NeXT Personal for detecting molecular residual disease in patients with early-stage triple-negative breast cancer receiving neoadjuvant therapy.

"B-STRONGER-1 builds on our earlier work in triple-negative breast cancer demonstrating the use of ultrasensitive MRD testing for monitoring neoadjuvant therapy response," said Richard Chen, MD, President and Chief Medical Officer of Personalis. "We are also excited to see NeXT Personal data presented from biopharma in new indications like cutaneous squamous cell carcinoma as we continue to expand evidence around NeXT Personal for a broad range of solid tumors."

Presentation Schedule

Late-Breaking Oral Presentation

  • Title: C-POST phase 3 trial of adjuvant (adj) cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC): Updated overall survival (OS) and outcomes from circulating tumour DNA (ctDNA) analyses

  • Presenter: Danny Rischin, M.D.; Peter MacCallum Cancer Centre

  • Abstract: LBA59 | Session: Rapid Oral - Melanoma and Other Skin Tumours

  • Time: Sun, 10/25/2026, 10:42 - 10:47 CET

  • Location: Granada Auditorium - Hall 4

Rapid Oral Presentation – B-STRONGER-1

  • Title: Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study

  • Presenter: Carlos Barcenas, M.D.; The University of Texas MD Anderson Cancer Center

  • Abstract: 540RO | Session: Rapid Oral - Breast Cancer, Early Stage

  • Time: Fri, 10/23/2026, 16:42 - 16:47 CEST

  • Location: Alicante Auditorium - Hall 6

Poster Presentations

  • Title: Ultrasensitive ctDNA kinetics predict early immunotherapy response and complement radiographic assessment in advanced cancer. (UC San Diego). Abstract # 4280P | Session: Translational Research and Biomarkers | Time: Fri, 10/23/2026, 15:15 - 16:00 CEST | Location: Poster Area - Hall 5

  • Title: Circulating tumour DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum- resistant ovarian cancer (PROC) treated with ubamatamab (uba). (Yonsei University Health System). Abstract # 1957P | Session: Investigational Immunotherapy | Time: Sat, 10/24/2026, 12:00 - 12:45 CEST | Location: Poster Area - Hall 5

  1. FinancePhilip Morris International Reports 2026 Third-Quarter & First Nine-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;Companies: Philip Morris InternationalThird-Quarter Reported Diluted EPS declined by 4.9% to $2.12; Adjusted Diluted EPS grew by 5.4% to $2.36; and by 5.8% excluding currency; STAMFORD, CT, October 21, 2026--Regulatory News: Philip Morris International Inc. (PMI) (NYSE: PM) today announces its 2026 third-quarter results.1 " We delivered an
  2. FinanceFunko, Inc.Funko to Announce 2026 Third Quarter Financial Results and Host Video Webcast on Thursday, November 5, 2026EVERETT, Wash., October 21, 2026--Funko, Inc. (Nasdaq: FNKO), a leading pop culture lifestyle brand, today announced that it will issue its financial results for the third quarter ended September 30, 2026, and host a video webcast on Thursday, November 5, 2026, at 4:30 p.m. ET. Ahead of the webcast, Fu
  3. FinanceTeledyne Technologies IncorporatedTeledyne Technologies Reports Third Quarter ResultsCompanies: Teledyne TechnologiesTHOUSAND OAKS, Calif., October 21, 2026--Teledyne Technologies Incorporated (NYSE:TDY) All-time record quarterly sales, operating profit and non-GAAP diluted earnings per share Third quarter net sales of $1,684.9 million, an increase of 9.4% compared with last year Third quarter GAAP diluted earnings p
  4. Northern Trust Corporation Reports Third Quarter 2026 Financial ResultsCompanies: Northern TrustCHICAGO, October 21, 2026--Northern Trust Corporation has released its third quarter 2026 financial results. Results can be found at https://www.northerntrust.com/about-us/investor-relations as well as on the corporation's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commissio
  5. SaaSCompvide, Inc.Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 2026SEATTLE, October 21, 2026--Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The c
  6. FinanceOneSpaWorld Holdings LimitedOneSpaWorld Announces Third Quarter Fiscal 2026 Financial Results on October 28, 2026NEW YORK, October 21, 2026--OneSpaWorld Holdings Limited, (NASDAQ: OSW), the pre-eminent global provider of health and wellness products and services on board cruise ships and in destination resorts around the world, announced today that it will release its Third Quarter Fiscal 2026 earnings on Wednesd